Badalona

• Fast-Track Therapeutic Model in Complicated Acute Appendicitis Recruiting
  2025-520777-39-00 6 2025-01-29 Complicated acute appendicitis
• A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting
  2023-510323-30-00 5 2025-01-24 First-line treatment of recurrent or metastatic PD-L1+ head and neck s
• "Multicenter randomized clinical trial to evaluate the cardioverter capacity of amiodarone pre-electrical cardioversion in persistent atrial … Recruiting
  2023-507201-34-00 6 2025-01-23 Atrial fibrillation
• IKS03 in Advanced B cell NHL Recruiting
  2024-512415-45-00 3 2025-01-14 Advanced B cell Non-Hodgkin Lymphomas
• RIO Trial Recruiting
  2024-514564-13-00 4 2025-01-02 HIV
• Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma Recruiting
  2024-511188-26-00 5 2024-12-20 Relapsed/refractory multiple myeloma in patients who have received 1 t
• A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting
  2023-508813-18-00 4 2024-12-18 Refractory Focal Onset Epilepsy
• This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP. Recruiting
  2023-507351-29-00 5 2024-12-03 Alzheimer's Disease Psychosis
• A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys … Recruiting
  2023-508960-31-00 5 2024-12-03 Metastatic HER2-positive breast cancer
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• Use of statins in patients with intracerebral hemorrhage Recruiting
  2024-511465-11-00 5 2024-11-20 Spontaneous lobar ICH
• An open-label study to assess reduction of daily asthma medication with tezepelumab in patients 12 to 80 years of age with severe asthma Recruiting
  2024-512113-41-00 5 2024-11-20 Severe Asthma
• Continuing Anticoagulants and Antiplatelets in Cold snare Polypectomy. Recruiting
  2024-511265-11-01 6 2024-11-19 patients who are requested a colonoscopy for any indication and are un
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-fibrosis) Recruiting
  2023-509912-27-00 5 2024-11-07 Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
• Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-neg … Recruiting
  2023-504620-26-00 4 2024-11-04 Triple negative breast cancer
• A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides difficile Infection: The Re … Recruiting
  2022-502972-22-00 5 2024-10-31 Clostridioides difficile infection.
• Phase II Study of Avelumab plus chemotherapy for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC). Mo … Recruiting
  2024-516777-77-00 4 2024-10-31 Resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GE
• Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH (ENLIGHTEN-Cirrhosis) Recruiting
  2023-510395-31-00 5 2024-10-30 Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Compensat
• A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can … Recruiting
  2023-509340-10-00 5 2024-10-29 Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
• A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc … Recruiting
  2024-511319-91-00 5 2024-10-23 Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
• A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting
  2023-509706-30-00 5 2024-10-18 Heart failure (HF)
• Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting
  2023-504724-25-00 5 2024-10-16 Primary Myelofibrosis
• 202301CPC Redefine-HF Recruiting
  2023-508581-15-00 5 2024-10-08 Heart condition
• A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting
  2023-508811-21-00 10 2024-09-25 Refractory Focal Onset Epilepsy

Showing 241–264 of 775 trials